VL 001
Alternative Names: VL-001Latest Information Update: 31 Mar 2025
At a glance
- Originator PulmoSIM Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 06 Mar 2025 Early research in Cancer in USA (unspecified route) before March 2025 (PulmoSIM Therapeutics pipeline, March 2025)